title: [Should we modify hemoglobin targets in CKD patients? FDA and EMEA statements].
authors.forename: A L
authors.initials: AL
authors.lastname: Martín de Francisco
authors.forename: P
authors.initials: P
authors.lastname: Aljama
authors.forename: M
authors.initials: M
authors.lastname: Arias
authors.forename: J L
authors.initials: JL
authors.lastname: Górriz
authors.forename: A
authors.initials: A
authors.lastname: Martínez Castelao
authors.forename: J
authors.initials: J
authors.lastname: Portolés
mesh_terms: D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D002908:Chronic Disease; D005060:Europe; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000150:complications / Q000628:therapy; D009938:Organizations; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D006454:Hemoglobins